Tranexamic acid: from trauma to routine perioperative use.

Area of Science:

• Anesthesiology
• Surgical Hemostasis
• Pharmacology

Background:

• Antifibrinolytic agents like tranexamic acid (TXA) are increasingly used to optimize hemostasis during surgery.
• TXA has proven efficacy and safety in trauma patients for reducing blood loss and transfusion needs.
• The application of TXA in non-trauma surgical patients without pre-existing coagulopathies remains a subject of debate due to concerns about thromboembolic events.

Purpose of the Study:

• To review the perioperative administration of TXA in non-trauma surgical populations.
• To assess the risk of thromboembolism associated with TXA use in these patients.
• To evaluate optimal dosing regimens and timing for TXA administration.

Main Methods:

• Systematic review of clinical studies on perioperative TXA in non-trauma surgery.
• Analysis of data regarding blood loss, transfusion rates, and thromboembolic events.
• Evaluation of different dosing strategies and administration timings.

Main Results:

• Perioperative TXA administration is linked to significant reductions in surgical blood loss and the need for blood transfusions.
• Current evidence suggests that TXA does not increase the risk of thromboembolic events in the studied populations.
• Optimal dosing and timing for TXA in non-trauma surgical settings are still under investigation and require further research.

Conclusions:

• TXA can be effectively integrated into perioperative blood management programs to minimize blood loss.
• Its use can help mitigate patient exposure to allogeneic blood transfusions.
• Further studies are needed to refine TXA protocols for non-trauma surgical applications.